Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 business update and financial results announced for quarter ended September 30, 2026.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 business update and financial results announced for quarter ended September 30, 2026
- Full operating and financial details contained in Exhibit 99.1, Cardiff Oncology’s accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 efficacy signal strengthening: median PFS not reached at 30 mg onvansertib plus FOLFIRI/bev versus approximately 11 months for combined SoC arms
- All remaining patients in the proposed Phase 3 regimen exceeded 21 months on treatment, with longest duration over 29 months
- Registrational Phase 3 trial preparation underway, with potential first-line RAS-mutated mCRC launch in Q1 2027
- Cash, equivalents and short-term investments $33.8M, funding projected through Q3 2027 at current spending plans
- Nine-month net loss $30.4M versus $38.6M, while operating cash use rose to $33.9M from $31.9M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.